Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates.

[1]  F. Davis,et al.  Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.

[2]  B. Brenner,et al.  Macromolecule transport across glomerular capillaries: application of pore theory. , 1979, Kidney international.

[3]  E. Åkerblom,et al.  Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. , 1983, International archives of allergy and applied immunology.

[4]  E. Åkerblom,et al.  Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. , 1984, International archives of allergy and applied immunology.

[5]  I. Yamamoto,et al.  Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase. , 1985, International journal of immunopharmacology.

[6]  J. Young,et al.  Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. , 1988, The Journal of biological chemistry.

[7]  D. Bruns,et al.  Oxidation of polyethylene glycols by alcohol dehydrogenase. , 1989, Biochemical pharmacology.

[8]  P. Caliceti,et al.  PREPARATION, PHYSICO-CHEMICAL AND PHARMACOKINETIC CHARACTERIZATION OF MONOMETHOXYPOLY(ETHYLENE GLYCOL)- DERIVATIZED SUPEROXIDE DISMUTASE , 1989 .

[9]  Effect of cytochrome P-450 inhibition and stimulation on intensity of polyethylene degradation in microsomal fraction of mouse and rat livers. , 1990, Biomaterials.

[10]  A. Abuchowski,et al.  The clinical efficacy of poly(ethylene glycol)-modified proteins , 1990 .

[11]  N V Katre,et al.  Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. , 1990, Journal of immunology.

[12]  R K Jain,et al.  Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.

[13]  Targetable polymeric drugs , 1990 .

[14]  T. Yamaguchi,et al.  Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. , 1991, Cancer research.

[15]  Toshiharu Yamaguchi,et al.  Comparative Pharmacokinetic Properties of Murine Monoclonal Antibody A7 Modified with Neocarzinostatin, Dextran and Polyethylene Glycol , 1991, Japanese journal of cancer research : Gann.

[16]  A. Sehon.  Suppression of Antibody Responses by Conjugates of Antigens and Monomethoxypoly(Ethylene Glycol) , 1991 .

[17]  V. Lee.  Peptide and protein drug delivery , 1991 .

[18]  C Delgado,et al.  The uses and properties of PEG-linked proteins. , 1992, Critical reviews in therapeutic drug carrier systems.

[19]  J. M. Harris,et al.  Poly(Ethylene Glycol) Chemistry Biotechnical and Biomedical Applications , 1992 .

[20]  Nandini V. Katre,et al.  The conjugation of proteins with polyethylene glycol and other polymers: Altering properties of proteins to enhance their therapeutic potential , 1993 .

[21]  R. Rabkin,et al.  Renal Uptake and Disposal of Proteins and Peptides , 1993 .

[22]  J. Svanvik,et al.  Hepatic excretion and metabolism of polyethylene glycols and mannitol in the cat. , 1993, Journal of hepatology.

[23]  Y. Ikada,et al.  Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. , 1994, Journal of pharmaceutical sciences.

[24]  Y. Ikada,et al.  Fate of water-soluble polymers administered via different routes. , 1995, Journal of pharmaceutical sciences.

[25]  P. Caliceti,et al.  Distribution of catalase, ribonuclease and superoxide dismutase modified by monomethoxy (polyethylene glycol) into rat central lymph and lymphatic nodes. , 1995, Physiological research.

[26]  Y. Ikada,et al.  Comparison of Body Distribution of Poly(vinyl alcohol) with Other Water‐soluble Polymers after Intravenous Administration , 1995, The Journal of pharmacy and pharmacology.

[27]  K. Ulbrich,et al.  Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. , 1995, European journal of cancer.

[28]  V. Mukku,et al.  Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol* , 1996, The Journal of Biological Chemistry.

[29]  P. Caliceti,et al.  Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly(ethylene glycol) , 1996 .

[30]  Y. Tsutsumi,et al.  Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency. , 1996, British Journal of Cancer.

[31]  K. Chester,et al.  Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. , 1996, British Journal of Cancer.

[32]  R. Offord,et al.  Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. , 1996, Bioconjugate chemistry.

[33]  D. Fisher,et al.  Polyethylene glycol modification: relevance of improved methodology to tumour targeting. , 1996, Journal of drug targeting.

[34]  L. Kwak,et al.  Improved conjugation of cytokines using high molecular weight poly(ethylene glycol): PEG-GM-CSF as a prototype , 1997 .

[35]  J. Chern,et al.  Poly(ethylene glycol) modification of β-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs , 1997, Cancer Immunology, Immunotherapy.

[36]  R. Shorr,et al.  The impact of polyethylene glycol conjugation on bovine hemoglobin's circulatory half-life and renal effects in a rabbit top-loaded transfusion model. , 2008, Artificial organs.

[37]  Samuel Zalipsky,et al.  Poly(ethylene glycol): Chemistry and Biological Applications , 1997 .

[38]  Y. Ikada,et al.  Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification , 1997 .

[39]  S. Han,et al.  Thermal/oxidative degradation and stabilization of polyethylene glycol , 1997 .

[40]  Kinam Park,et al.  Controlled drug delivery : challenges and strategies , 1997 .

[41]  L. Kwak,et al.  Conjugation of High-Molecular Weight Poly(ethylene glycol) to Cytokines: Granulocyte-Macrophage Colony-Stimulating Factors as Model Substrates , 1997 .

[42]  R. Hoffman,et al.  Polyethylene glycol conjugation of recombinant methioninase for cancer therapy. , 1998, Protein expression and purification.

[43]  D. Fisher,et al.  PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. , 1998, International journal of hematology.

[44]  F. Veronese,et al.  Stabilization of substances in circulation. , 1998, Bioconjugate chemistry.

[45]  M. Whitlow,et al.  Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. , 1999, Bioconjugate chemistry.

[46]  P. Caliceti,et al.  Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers. , 1999, Bioconjugate chemistry.

[47]  J. Chern,et al.  Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. , 1999, Bioconjugate chemistry.

[48]  Mariangela Spitali,et al.  Therapeutic antibody fragments with prolonged in vivo half-lives , 1999, Nature Biotechnology.

[49]  P. Caliceti,et al.  Immunogenic and tolerogenic properties of monomethoxypoly(ethylene glycol) conjugated proteins. , 1999, Farmaco.

[50]  C. Edwards.  PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases , 1999, Annals of the rheumatic diseases.

[51]  M. Hashida,et al.  Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives. , 1999, The Journal of pharmacology and experimental therapeutics.

[52]  R. Mehvar.  Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. , 2000, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[53]  L. Old,et al.  Pharmacokinetics and microdistribution of polyethylene glycol‐modified humanized A33 antibody targeting colon cancer xenografts , 2000, International journal of cancer.

[54]  D. Wyss,et al.  Identification of the major positional isomer of pegylated interferon alpha-2b. , 2000, Biochemistry.

[55]  R. Brundage,et al.  Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. , 2000, The Journal of pharmacology and experimental therapeutics.

[56]  J. Chern,et al.  Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. , 2000, Bioconjugate chemistry.

[57]  Z. Shahrokh,et al.  Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity. , 2000, International journal of pharmaceutics.

[58]  I. Lasters,et al.  Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase. , 2000, Blood.

[59]  M. Wilchek,et al.  Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies , 2000, Cancer Immunology and Immunotherapy.

[60]  H. Maeda,et al.  Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue. , 2000, Cancer research.

[61]  J. M. Harris,et al.  Pegylation: a novel process for modifying pharmacokinetics. , 2001, Clinical pharmacokinetics.

[62]  P. Caliceti,et al.  Immunological properties of uricase conjugated to neutral soluble polymers. , 2001, Bioconjugate chemistry.

[63]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[64]  F. Veronese.  Peptide and protein PEGylation: a review of problems and solutions. , 2001, Biomaterials.

[65]  A. P. Chapman,et al.  PEGylated antibodies and antibody fragments for improved therapy: a review. , 2002, Advanced drug delivery reviews.

[66]  K. Whitcomb,et al.  Enteral Bioavailability of Human Granulocyte Colony Stimulating Factor Conjugated with Poly(ethylene glycol) , 2004, Pharmaceutical Research.